Program
gotistobart
Also written as “ONC-392”, “Gotistobart” and “ONC-392 low”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Prostatic Neoplasms, led by OncoC4.
Furthest: phase 3, since Dec 26, 20225 company-led studies, 5 open or runningNext primary completion: Nov 30, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| OncoC4 | 55 open or running | phase 3since Dec 26, 2022 | Oct 24, 2019 | Nov 30, 2026phase 2 · NCT05682443 |
Also a collaborator on its studies: Merck and BioNTech.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 24, 2019First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04140526 · 733 enrolled · United States, Australia
- Jun 30, 2022Phase 2 study in Ovarian NeoplasmsNCT05446298 · 58 enrolled · United States
- Dec 26, 2022Phase 2 study in Metastatic Castration-resistant Prostate CancerNCT05682443 · 148 enrolled · United States
- Dec 26, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05671510 · 630 enrolled · United States, Australia, Belgium and more
- Jun 15, 2026Phase 3 study in Advanced Solid TumorNCT07659379 · 20 planned · United States
Ahead
- Nov 30, 2026Primary completion: phase 2 study in Metastatic Castration-resistant Prostate CancerNCT05682443
- Dec 31, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04140526
- Aug 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05671510
- Jul 1, 2036Primary completion: phase 3 study in Advanced Solid TumorNCT07659379
TargetBeta
CTLA4 →read by rule
“A humanized, pH-sensitive immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), ”NCIt, by rule
Other programs on CTLA4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tremelimumabrule | AstraZeneca | phase 3 | 47 |
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| Anti-CTLA-4 Monoclonal Antibody SHR-8068rule | Jiangsu HengRui Medicine | phase 3 | 16 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-CTLA-4 Monoclonal Antibody IBI310rule | Innovent Biologics | phase 3 | 11 |
| zalifrelimabrule | Agenus | phase 2 | 6 |
| porustobartrule | harbour-biomed-guangzhou-co-ltd | phase 2 | 5 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| GB268rule | eddingpharm-zhuhai-co-ltd | phase 2 | 2 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07659379Advanced Solid Tumor · United States | 3 | By invitation | Jul 1, 2036 | 20 |
| NCT05682443Metastatic Castration-resistant Prostate Cancer · United States | 2 | Active, not recruiting | Nov 30, 2026 | 148 |
| NCT05671510Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 3 | Active, not recruiting | Aug 31, 2027 | 630 |
| NCT05446298Ovarian Neoplasms · United States | 2 | Active, not recruiting | Aug 30, 2026 | 58 |
| NCT04140526Carcinoma, Non-Small-Cell Lung · United States, Australia | 2 | Active, not recruiting | Dec 31, 2026 | 733 |
How it is read
Names in the registry
- “ONC-392”, 2 entries
- “Gotistobart”, 2 entries
- “ONC-392 low”, 1 entry
- “ONC-392 high”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Ovarian Neoplasms, 1 study
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.